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Abstract
Background: Aurora-A is a bona-fide oncogene whose expression is associated with genomic instability and
malignant transformation. In several types of cancer, gene amplification and/or increased protein levels of Aurora-A
are a common feature.
Results: In this report, we describe that inhibition of cell proliferation is the main effect observed after transient
overexpression of Aurora-A in primary human cells. In addition to the known cell cycle block at the G2/M
transition, Aurora-A overexpressing cells fail to overcome the restriction point at the G1/S transition due to
diminished RB phosphorylation caused by reduced Cyclin D1 expression. Consequently, overexpression of Cyclin
D1 protein is able to override the Aurora-A mediated G1 block. The Aurora-A mediated cell cycle arrest in G2 is
not influenced by Cyclin D1 and as a consequence cells accumulate in G2. Upon deactivation of p53 part of the
cells evade this premitotic arrest to become aneuploid.
Conclusion: Our studies describe that an increase of Aurora-A expression levels on its own has a tumor
suppressing function, but in combination with the appropriate altered intracellular setting it might exert its
oncogenic potential. The presented data indicate that deactivation of the tumor suppressor RB is one of the
requirements for overriding a cell cycle checkpoint triggered by increased Aurora-A levels.
Background
The family of the Aurora/Ipl1p kinases is evolutionally
conserved. These serine/threonin kinases fulfill important
functions in the control and regulation of the centrosome
cycle, spindle assembly, chromosome condensation,
microtubule-kinetochore attachment, the spindle-assembly
checkpoint, cytokinesis, as well as entry into and exit from
mitosis. In mammals, the Aurora kinase family comprises
three members designated Aurora-A, -B, and -C [1-3].
One member of this family, Aurora-A (AURKA), also
known as serine/threonine kinase 15 (STK15), aurora2
or aurora related kinase (hARK1), is decisively involved
in centrosome duplication, separation, as well as
maturation [4]. Its functions are required to ensure pro-
gression through mitosis [5-7], complete cytokinesis [8]
and genomic integrity [4,9].
The gene encoding Aurora-A maps to chromosome
20q13.2, a region that is frequently amplified in human
cancers including colorectal [10], breast [4], pancreatic
[11] and bladder cancer [12]. Consequently, mRNA and
protein levels of Aurora-A are also increased in those
types of carcinoma. In addition, overexpression of Aur-
ora-A has been found in a variety of human tumors and
cancer cell lines, independent of gene amplification [4,13]
(reviewed in [14]). In accordance, ectopic Aurora-A
expression transforms immortalized NIH 3T3 cells in
tissue culture [4,10].
Although accumulating evidence emphasizes an onco-
genic role of overexpressed Aurora-A in carcinogenesis,
several reports describe that in primary mouse models
Aurora-A overexpression often fails to induce cancer,
even in p53 deficient animals. In mammary glands, peri-
odic Aurora-A overexpression has been shown to cause
mitotic abnormalities and massive apoptosis. Hyperpla-
sia of the surviving cells was observed, however no
malignant tumors developed [15]. Another study reports
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plasia [16]. It was furthermore observed that increased
Aurora-A expression in liver caused premitotic arrest
during liver regeneration [17]. Corroborating knock-out
studies revealed that Aurora-A may also act as a hap-
loinsufficient tumor suppressor. Whereas Aurora-A null
mice died early during embryonic development, Aurora-
A heterozygosity resulted in a significantly increased
tumor incidence [18].
In this report, we studied the effect of Aurora-A over-
expression in primary human cells and show that high
levels of Aurora-A inhibit cell proliferation at both G1/S
and G2/M transition.
Results
Overexpression of Aurora-A inhibits cell proliferation in
primary human cells
Our initial interest was directed towards the influence of
ectopic Aurora-A overexpression on cell proliferation and
cell cycle profile of primary human lung fibroblasts (Wi-38
cells). To this end, Aurora-A expression in logarithmically
growing Wi-38 cells was elevated by using an adenoviral
vector to reach protein levels observed in tumor cell lines
with gains of chromosome 20q, including the gene locus of
AURKA (Figure 1A) [19]. By performing a growth curve
experiment 24 hours post-infection, the influence of Aur-
ora-A overexpression on cell proliferation was determined.
While cells infected with the control virus expressing lacZ
increased their number six-fold within 9 days, Aurora-A
expression inhibited proliferation efficiently. Within
10 days the number of cells remained unchanged (Figure
1B). These data suggest that Aurora-A overexpression actu-
ally inhibits cell proliferation of primary human cells.
To investigate at which phases of the cell cycle Aurora-
A overexpression inhibits proliferation, PI-staining of
logarithmically growing Wi-38 cells was performed 24,
48 and 72 hours after infection of the cells with lacZ and
Aurora-A expressing viruses (Figure 1C). Flow cyto-
metric analysis of the DNA content revealed that as a
consequence of Aurora-A overexpression the amount of
cells in S-phase successively declines (Figure 1C, left
panel). In addition to an increase of cells with doubled
DNA content (16% compared to 10%), we detected an
obvious and significant accumulation of cells in G1 phase
in response to Aurora-A overexpression after 72 hours
(79% compared to 72%) (Figure 1C, right panel). These
data indicate that Aurora-A might not only be involved
in a checkpoint at the G2/M transition, but can also
interfere with cell cycle progression in G1 phase.
S-phase entry is inhibited by Aurora-A expression in
quiescent cells
To confirm the observed inhibitory effect of Aurora-A
in G1 phase, Wi-38 cells were serum starved for 24
hours before infection with the Aurora-A adenovirus.
Again, the adenoviral titer necessary to reach Aurora-A
expression levels similar to those in a serum starved
tumor cell line (T98G) was determined (Figure 2A).
Aurora-A expression had no influence on the amount
of cells in quiescence. 48 hours after infection serum
starved Wi-38 cells were released from G0 phase by addi-
tion of growth medium containing 20% serum. 26 hours
after serum addition, more than 50% of the cells exited
quiescence in control cells (38% in S- and 15% in G2-
phase), while in Aurora-A overexpressing cells only
about 10% of cells entered S-phase (Figure 2B). Accord-
ingly,
3H-thymidine incorporation assay revealed that
upon serum stimulation incorporation of thymidine was
only slightly increased (3-fold) when cells express Aur-
ora-A, whereas control cells have about 15-fold higher
incorporation rates than their arrested counterparts
(Figure 2C). These data verify the results from the PI
stainings and demonstrate that overexpression of
Aurora-A in quiescent cells prevents DNA replication by
causing either defects in G1-phase exit or S-phase entry.
Kinase activity is dispensable for the inhibitory function
of Aurora-A prior to S-phase entry
To investigate if the observed interference with induction
of DNA replication is connected to the kinase activity of
overexpressed Aurora-A protein, quiescent Wi-38 cells
were infected with adenoviruses expressing Aurora-A
mutated at amino acid 162 to Arg (AurA
K162R). This
mutant had previously been described as kinase deficient
[8]. Similar to the wildtype (wt) protein, expression of
AurA
K162R repressed S-phase entry of quiescent cells
(Figure 2B). Corresponding to the DNA content analysis,
initiation of DNA replication was inhibited by AurA
K162R
as measured by thymidine incorporation (Figure 2C).
These data indicate that the kinase activity is not
required for the blockage of cells in G1 phase in response
to expression of Aurora-A protein.
The G0/G1 arrest is not caused by the interplay of
Aurora-A with p53, RASSF1 or RasGAP
Previous studies have shown that Aurora-A directly
binds to p53. Although the reported effects of this inter-
action are phosphorylation-dependent inhibition of p53
function [20] and stability [21], we next examined if the
triggering of an G0/G1 arrest by overexpression of
Aurora-A in serum-deprived cells is influenced by p53
levels or functions. Immunoblotting demonstrated
that p53 levels in arrested, Aurora-A overexpressing
Wi-38 cells were increased compared to control cells
(Figure 3A). However, since after serum addition p53
expression declined more rapidly in Aurora-A overex-
pressing cells, after 16 hours the p53 protein levels were
comparable to control cells (Figure 3A). Nonetheless it
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Page 2 of 12is possible that elevated p53 levels in arrested cells could
be responsible for the Aurora-A-mediated obstruction of
cell cycle progression in G0/G1. Adenoviral expression
of p53
V143A protein, which was described to be dominant
negative with respect to the transcriptional activities [22],
was utilized to evaluate the involvement of p53 in the
observed G1-arrest. As control, cells expressing p53
wt pro-
tein were analyzed. As anticipated, overexpression of
p53
wt decelerated cell cycle progression of control cells. In
combination with p53
wt the Aurora-A triggered inhibition
of G0/G1 exit was yet effective. Even though we observed
an accelerated cell cycle progression of control cells when
p53 functions were inhibited, p53
V143A failed to abrogate
the Aurora-A-mediated cell cycle stop (Figure 3B). In
addition, p53 expression levels were reduced by transfect-
ing siRNA. Although the p53 protein levels were efficiently
decreased in cells treated with a p53-specific siRNA (lanes
7 and 8 in Figure 3C) as compared to cells transfected
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Figure 1 Influence of Aurora-A overexpression on cell cycle. (A) Wi-38 cells were infected with adenoviruses expressing either Aurora-A or
control (lacZ) proteins. Overexpressed protein levels were compared to T98G (glioblastoma), VM24, and VM7 (melanoma) cell lines. (B) Wi-38
cells overexpressing Aurora-A were tested in a growth curve experiment against cells infected with a control virus. The results of two
independent experiments are depicted. (C) Logarithmically growing Wi-38 cells were infected with the viruses expressing the indicated proteins
and DNA content was measured 24, 48 and 72 hours after infection. The time curve shows the percentage of cells in G1 and S-phase from a
representative experiment. The histograms and the respective cell cycle analysis of the 72 hours time point is depicted. Bars illustrate means and
standard deviation of four independent experiments. Statistical analysis was done using an unpaired, two-sided t-test. * P < 0.05.
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Page 3 of 12with a control siRNA (lanes 3 and 4 in Figure 3C), cells
predominantly arrested in G0/G1-phase when Aurora-A
was overexpressed (Figure 3C). These data suggest that
p53 is not responsible for the inhibitory function of Aur-
ora-A prior to transition from G1- to S-phase.
Two other established interaction partners of Aur-
ora-A protein, RASSF1 [23] and RasGAP proteins
[24], are known to associate with and modulate Ras
activity and are therefore possibly involved in the inhi-
bition of DNA replication by excessive amounts of
Aurora-A. We hence analyzed if Aurora-A influences
Ras-mediated signaling pathways by monitoring phos-
phorylation of ERK1/2 (extracellular signal-regulated
kinase) for MAPK (mitogen-activated protein kinase)
pathway and phosphorylation of ribosomal protein S6
for the PI3K (phospho-inosityl-3-kinase) pathway. To
this end, quiescent Aurora-A expressing and control
cells were induced by addition of serum. After 5 and
20 minutes the intensity of the pERK signaling was
comparable in both control and Aurora-A virus-trea-
ted cells. Similar intensities of phosphorylated riboso-
mal protein S6 levels were observed after 20 minutes.
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Figure 2 G1 cell cycle arrest mediated by Aurora-A wildtype and K162R. (A) Serum starved Wi-38 cells were infected with adenoviruses
expressing either Aurora-A or control (lacZ) proteins. Cell were induced by serum addition and protein levels were compared to those of
equally treated T98G cells 26 hours post induction (B) Arrested Wi-38 cells were infected with adenoviruses expressing the proteins indicated. 48
hours after infection serum was added and PI-stainings were collected. A representative of three experiments is shown. (C) Cells were treated as
in (B) and a
3H-thymidine incorporation assay was performed. Bars depict means and SD of three independent experiments.
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Page 4 of 12After 5 minutes phosphorylation of S6 was even
enhanced in Aurora-A expressing cells (Figure 3D).
These data suggest that expression of Aurora-A does
not interfere with activation of Ras-mediated signaling
indicating that the interaction with RASSF1 and Ras-
GAP cannot explain the inhibitory role of Aurora-A in
cell cycle progression.
Aurora-A overexpression in quiescent cells negatively
influences Cyclin D1-mediated activities
To elucidate which regulatory pathways prior to S-phase
entry were affected by Aurora-A overexpression, we
analyzed the expression of molecules involved in cell
cycle regulation. RNA from lacZ and Aurora-A expres-
sing cells in G0 and late G1 phase (16 hours after
serum induction) was extracted to perform an expres-
sion analysis using Human BD Atlas cDNA expression
array 1.2.1. In response to serum addition, 65 of the
genes assayed by the expression array changed their
mRNA levels more than 2-fold in control treated cells.
Only 6 of these genes showed a 2-fold difference in
expression between Aurora-A expressing and control
cells indicating that Aurora-A expression interferes with
their response to serum addition. 5 out of those 6 genes
were upregulated in response to serum in control cells
while their levels in cells expressing Aurora-A were
comparable to those in quiescent cells. These genes
include Cyclin D1, the fibroblast growth factor-7 (FGF7/
KGF/HBGF-7), the monocyte chemotactic protein 1 pre-
cursor (MCP1, CCL-2), the insulin-like growth factor
binding protein 3 (IGFBP3), and plasminogen activator
inhibitor Type 1 (PAI1). p19
INK4 d (CDKN2D), a known
inhibitor of the Cyclin D/CDK4/6 complexes, was
reduced in response to serum addition in control cells,
while its levels remained high in Aurora-A expressing
cells (Figure 4A). Since we did not observe an influence
of Aurora-A expression on MAPK and PI3K pathways
(compare Figure 3), we decided to focus on Cyclin D1
involving pathways. Cyclin D1 (CCND1) is known to
activate CDK4 and CDK6, a key event in mediating G1/
S transition [25]. To confirm the differences detected in
the expression arrays, synchronized lacZ and Aurora-A
overexpressing Wi-38 cells were analyzed by Northern
blot analysis. As expected, in control Wi-38 cells Cyclin
D1 levels were increased when quiescent cells were
released into the cell cycle. In cells overexpressing
Aurora-A, Cyclin D1 mRNA levels were reduced in
absence and presence of serum. Although addition of
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Figure 3 Importance of known Aurora-A interactions for cell cycle inhibition. (A) Wi-38 cells were arrested in G0 by serum deprivation and
infected with adenoviruses expressing Aurora-A or control virus expressing lacZ and analyzed by immunoblotting with the antibodies indicated.
(B) Quiescent cells were infected with adenoviruses expressing the indicated proteins and analyzed by immunoblotting and PI staining at time
points 0 and 26 hours after serum addition. (C) Serum arrested cells expressing Aurora-A or lacZ were transfected with the indicated siRNA 24
hours prior to serum addition. At the indicated time points cells were harvested and analyzed as in (B). (D) Serum deprived cells infected with
control or Aurora-A expressing viruses were harvested at the indicated times and analyzed by immunoblotting with antibodies recognizing
phosphorylation of ERK1/2 and ribosomal protein S6, respectively. For all illustrations, representatives of at least two independent experiments
are shown.
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INK4d. (B) Verification of the array data was done using Northern blot analysis with a Cyclin D1 probe
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One of 3 Northern blots from independent experiments is shown. The expression level ratios of Cyclin D1 were calculated after densitometric
analysis using ImageQuant software (Molecular Dynamics, Sunnyvale, CA) and normalized to GAPDH. Serum-deprived control cells were set to 1.
(C) Immunoblot of equally treated cells was performed and assayed for Cyclin D1 protein expression. (D) At the indicated times, immunoblotting
of serum released cells expressing either lacZ (control) or Aurora-A was performed with the antibodies indicated.
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Page 6 of 12serum resulted in an about 3-fold increase of Cyclin D1
expression the yielded mRNA amounts failed to signifi-
cantly exceed the levels of serum starved control cells
(Figure 4B). Corresponding to the mRNA analysis,
Cyclin D1 protein expression in Aurora-A expressing
cells was less pronounced and increased only twofold
( F i g u r e s4 B ,4 C ) .T ot e s tw h e t h e rt h i so b s e r v a t i o ni s
exclusive for Wi-38 cells, normal adult skin fibroblasts
Hs 545 SK were tested and showed a similar decrease in
Cyclin D1 levels upon Aurora-A overexpression (data
not shown). These data indicate that expression of
Aurora-A might result in repression of Cyclin D1/
CDK4/6-mediated kinase activity. Therefore we analyzed
the influence of Aurora-A expression on phosphoryla-
tion of Serine 795 in the retinoblastoma gene product
(RB), a key Cyclin D1/CDK4/6 substrate site [26]. While
phosphorylation of RB was observed 18 hours after
serum induction in control cells, Aurora-A infected cells
exhibited no detectable RB-phosphorylation (Figure 4D).
We therefore conclude that a negative influence of
Aurora-A expression on Cyclin D1 levels may contribute
to diminished RB-phosphorylation.
Expression of Cyclin D1 overrides the Aurora-A mediated
block in G1
To test the significance of the observed reduction of
Cyclin D1 activity for the inhibitory role of Aurora-A
on cell cycle progression after exit of G0 phase, quies-
cent Wi-38 cells were infected with viruses expressing
lacZ, Aurora-A, Cyclin D1 or the combination of Aur-
ora-A and Cyclin D1. On its own, Cyclin D1 expres-
sion had no influence on cell cycle progression of
serum induced Wi-38 cells. In contrast, if Aurora-A
overexpressing cells were co-infected with viruses cod-
ing for Cyclin D1, 40 to 50% of the cells were able to
enter the cell cycle in response to serum addition (Fig-
ure 5A). Additionally, immunoblot-analysis revealed
that Cyclin D1 expression in cells overexpressing Aur-
ora-A resulted in restoration of RB-phosphorylation
(Figure 5B). These data demonstrate that Cyclin D1
expression is sufficient to abrogate the G1 phase
checkpoint induced by Aurora-A. To assess if restora-
tion of RB phosphorylation is predominantly necessary
to overcome the Aurora-A mediated G1-block, we
reduced the RB levels using siRNA (Figure 5C). Down-
regulation of RB increased the proportion of cells able
to transit the G1/S boundary, even though the override
of the Aurora-A-mediated G1-arrest was less efficient
as compared to Cyclin D1 overexpression. This differ-
ence may be due to other Cyclin D1 functions or the
only partial knock-down of RB protein (see Figure 5C).
However, hypophosphorylation of RB is one determi-
nant hindering cell cycle progression in the presence
of excessive Aurora-A.
Cyclin D1 has no effect on the G2/M arrest in response to
Aurora-A overexpression
We subsequently investigated the effect of Cyclin D1
expression on the G2/M arrest in response to Aurora-A
overexpression. Therefore, logarithmically growing Wi-
38 cells were infected with either Aurora-A expressing
viruses alone or with a combination of Aurora-A and
Cyclin D1. This Cyclin D1 co-expression with Aurora-A
resulted in accumulation of cells in G2/M (~ 35%
instead of ~ 15%) after 3 days (Figure 6A). Growth
curve analysis revealed that Cyclin D1 fails to override
the inhibition of cell proliferation induced by elevated
Aurora-A levels, indicating that the G2/M block is inde-
pendent of Cyclin D1 activity (Figure 6B). To verify this
observation, cell cycle progression of cells expressing
Aurora-A and/or Cyclin D1 was additionally measured
48 hours after serum addition (Figure 6C). At this time
point the majority of the control treated cells have exe-
cuted mitosis and the G1 peak is again elevated. The
cells overexpressing Aurora-A remain blocked in G1.
Only the 10 to 15% of cells which are able to enter the
cell cycle progress to G2 (compare Figure 2). If Cyclin
D1 is co-expressed with Aurora-A, the cells able to
evade the G1 block accumulate in G2/M phase indicat-
ing that Cyclin D1 expression overrides the Aurora-A
mediated G1-, but not the G2-block (Figure 6C).
According to the literature, the mechanisms responsi-
ble for the G2/M block are unknown, but it is docu-
mented that lack of p53 activity facilitates the escape of
the premitotic Aurora-A block [8]. Therefore we tested
if expression of dominant negative p53 is able to over-
ride the block triggered by concomitant Aurora-A and
Cyclin D1 expression in serum released cells. In line
with the observations of Meraldi et al. [8], abrogated
p53 function resulted in a remarkable increase of
cells with a more than 4N DNA content as measured
48 hours and 72 hours after serum addition (Figure 6D).
Taken together these results indicate that deactivation
of RB and p53 controlled checkpoints are required for
the role Aurora-A plays as inducer of aneuploidy.
Discussion
Aneuploidy is a common characteristic of cancer cells
and is considered as an important tumor promoting
force. Numerical and structural alterations of chromo-
somes are often the consequences of failures in a sur-
veillance mechanism called the mitotic checkpoint. In
many tumors Aurora-A overexpression is a frequent
alteration associated with aneuploidy and chromosomal
instability. Thus, Aurora-A has been regarded as an
oncogene.
In this study we present data indicating that in pri-
mary cells, Aurora-A overexpression in first instance
decelerates or blocks cell proliferation. This observation
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A overexpression causes an arrest of cell cycle progres-
sion at the G2/M transition [8,17].
In contrast to these earlier reports, we observed that
increased levels of Aurora-A protein not only exhibit an
inhibitory function during G2/M phase, but additionally
interfere with progression through G1 phase. Since in
normal cells Aurora-A functions are primarily associated
with processes important for regulating G2/M transi-
tion, a role of Aurora-A prior to S-phase entry is inter-
esting. Only few publications have hinted that there may
be non-mitotic functions of Aurora-A. Its interaction
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Figure 5 Influence of Cyclin D1 co-expression along with Aurora-A on G1/S arrest. G0 arrested Wi-38 cells were infected with the viruses
expressing the indicated proteins 24 hours after serum depletion. 48 hours after infection, serum was added. (A) At the indicated time points, PI-
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Page 8 of 12with a histone deacetylase complex induces cilia disas-
sembly [27] and it is part of an aPKC-Aurora-A-NDEL1
p a t h w a yp l a y i n gar o l ei nn e u r o nd i f f e r e n t i a t i o n[ 2 8 ] .
Additionally, a growth inhibitory role of Aurora-A was
reported in Drosophila, where Aurora-A inhibits self
renewal of neuroblasts [29,30].
Interestingly, the enzymatic activity of Aurora-A
seems to be dispensable for its cell cycle suppressing
functions. As it has been reported for the G2/M arrest
[8], increased levels of the catalytically inactive Aurora-
A
K162R are also able to activate regulative mechanisms
to halt cell cycle progression during G0/G1, inferring
that the tumor suppressive roles of the Aurora-A pro-
tein are not dependent on its kinase activity. Since the
same mutant fails to function in transformation of
immortalized rodent cells [10], it is likely that the onco-
genic functions of this Aurora family member may be
assigned to enhanced kinase activity. Although the eluci-
dated molecular mechanisms involving Aurora-A are
connected to its kinase activity, there are data indicating
that Aurora-A could exert kinase independent functions
[31]. While in case of Aurora-A inactivation by antibody
injection cells showed defects in completing cytokinesis
[32], inhibition of Aurora-A with a kinase inhibitor did
not affect cytokinesis in the analyzed cell lines [33],
arguing for the existence of a kinase-independent mode
of action.
We observed that the majority of quiescent Aurora-A
overexpressing cells fail to exit G0/G1 phase. Concomi-
tantly, Cyclin D1 levels are diminished and RB-
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involvement of RB in the G0/G1 block induced by
Aurora-A expression can also explain why ectopic Aur-
ora-A expression during liver regeneration only caused a
premitotic arrest, but failed to arrest cells prior to S-
phase entry [17]. Deletion of RB has been shown to
have no impact on hepatic proliferation, while the role
of RB in cell cycle control is well established in most
other cell models [34].
Since the changes in Cyclin D1 protein and mRNA
expression levels are comparable, we can exclude that
Aurora-A interactions with components of the protein
degradation machinery are responsible for the reduced
Cyclin D1 levels. In subsequent studies the exact
mechanisms of how Aurora-A expression decreases
Cyclin D1 mRNA levels have to be elucidated.
Although Cyclin D1 co-expression can largely override
the Aurora-A mediated inhibition of S-phase entry, we
cannot exclude that additional defects in other pathways
hinder cell cycle progression. Beside the changed
expression of Cyclin D1 and p19
INK4d, four other mole-
cules usually induced by serum addition show a more
than twofold change of their expression upon increased
Aurora-A levels. The gene products of these candidates
are secreted to the cellular environment. Whereas MCP-
1 and FGF 7 are usually involved in paracrine signaling
pathways [35,36], PAI-1 and IGFBP3 were reported to
modulate autocrine signaling cascades [37,38] and may
therefore also affect the cell cycle exit of quiescent Wi-
38 cells. Yet although activation of MAPK and PI3K
pathways was not inhibited by Aurora-A overexpression,
it is still possible that the reduced activation of these
proteins can influence processes other than RB phos-
phorylation and thereby explain why Cyclin D1 cannot
completely abrogate the inhibitory effect of Aurora-A in
G1. Nonetheless, even though re-expression of Cyclin
D1 overrides a G1 arrest induced by Aurora-A, restora-
tion of Cyclin D1 activity is not sufficient to overcome
arrest at G2/M and subsequently the antiproliferative
effect elicited by Aurora-A.
Similar to the G1 arrest, the mechanisms responsible
for the inhibition of G2/M transition by excessive Aur-
ora-A levels have not yet been elucidated. However, it
was reported that p53 functions are involved in mainte-
nance of this arrest [8], although p53 null cells respond
with a premitotic arrest to Aurora-A overexpression
[17]. Cells escaping this block undergo tetraploidization
[8]. Accordingly, we report that p53 functions are dis-
pensable for the G0/G1 arrest induced by Aurora-A, but
expression of dominant negative p53 facilitated the
escape of Aurora-A/CyclinD1 co-expressing cells from
the premitotic arrest, resulting in the formation of an
aneuploid subpopulation.
Conclusion
It is a common phenomenon that an opportune accumu-
lation of defects can make a protein gain tumor-promot-
ing properties. This can be observed in the case of the
Ras oncogenes, which primarily induce senescence [39],
but are a strong tumor-promoting force in an appropri-
ately altered intracellular setting. We conclude that an
increase of Aurora-A expression levels on its own results
in repression of proliferation, most likely by inducing cell
cycle checkpoints, but in combination with other altera-
tions, which include deactivation of the tumor suppressor
RB, might exert its oncogenic potential.
Materials and methods
Cell culture, growth curves and siRNA
Embryonic lung fibroblasts (Wi-38), adult human skin
f i b r o b l a s t sH s5 4 5S K( C R L - 7 318) and the glioblastoma
cell line T98G were obtained from ATCC and cultured
using DMEM growth medium containing 10% fetal
bovine serum (FBS) and supplemented with penicillin
(100 U/ml), streptomycin (100 μg/ml) and pyruvate.
Melanoma cell lines VM7 and VM24 were established
from primary tumor samples and cultured as described
[40]. Synchronization of cells in certain phases of the
cell cycle was achieved by serum starvation as described
in ref. [41]. Growth curves were performed as described
elsewhere [42].
For siRNAs transfections 10
5 cells were plated in 6-well
dishes and serum starved for 24 hours before cells were
infected with adenovirus. 48 hours post-infection, siRNAs
were transfected using oligofectamine according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA).
The sequences used were: sip53 5’-GCAUGAACCG-
GAGGCCCAUTT-3’ and siRb 5’-GAUACCAGAUCAU-
GUCAGATT-3’.
Adenovirus preparation
Using the vectors kindly provided by Dr. Erich A. Nigg
(Max-Planck-Institut für Biochemie, Martinsried), the
coding sequences of wild type Aurora-A and the kinase
deficient mutant K162R were subcloned into the pADlox
recombination vector via BamH1 and Bgl2 sites. The
coding sequences of Cyclin D1 and p53 were amplified
from human cDNA using the primers 5’-TCTGGGATC-
CATGGAACACCAGCTCCTGTGCTGC-3’ (Cyclin D1
fw), 5’-GTATGAATTCTCAGATGTCCACGTCCCG-
CACGTC-3’ (Cyclin D1 rev), 5’-GAATGGATCCATG-
GAGGAGCCGCAGTCAGATCC-3’ (p53 fw) and 5’-
TCTAGAATTCTCAGTCTGAGTCAGGCCCTTCTG
TC-3’ (p53 rev) and cloned into the pADlox vector via
introduced BamH1 and EcoR1 sites. The p53 mutant
V143A was prepared by site directed mutagenesis. The
constructs were verified by restriction digestion and
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Page 10 of 12sequencing. Recombinant viruses were produced
as described in ref. [43] and designated AdAurA and
AdAurA
K162R,A d p 5 3
wt, Adp53
V143A and AdCycD1. A
virus expressing lacZ was used as a control [42]. All
infections were performed at a multiplicity of infection
(MOI) of 50 if not indicated otherwise.
Propidium iodide based DNA content
analysis (PI-staining)
Cells were trypsinized and collected by centrifugation.
Cell pellets were washed with PBS and fixed in ice
cold 70% ethanol. Cells were again centrifuged, washed
twice and resuspended in 300 μl PBS and subsequently
stained by addition of Propidium iodide (50 μg/ml)
and RNase A (500 μg/ml). Measurements were per-
formed on a BD FACScalibur and analyzed with
MODFIT software.
Thymidine incorporation assay
Serum starved cells were infected with recombinant ade-
novirus and subsequently released into the cell cycle by
addition of 20% serum. 17 hours after induction, the
growth medium was replaced with serum free medium
and to each well [
3H]-thymidine (1.25 μCi/ml) was
added. After incubation for 1 hour, medium was aspi-
rated and cells were harvested in 500 μl lysis buffer
(0.2% SDS, 20 mM EDTA). After precipitation of the
DNA by addition of 500 μlo f2 0 %T C A ,D N Aw a s
spotted on fiberglass filters which were then submerged
in scintillation liquid. Detection was performed on a
Packard 2200TR scintillation counter.
Protein extraction from cell lines
Protein extracts of cell lines were obtained by adding
whole cell extract buffer (20 mM HEPES pH 7.6, 0.4 M
NaCl, 1 mM EDTA, 5 mM NaF, 25% Glycerol, 0.1%
NP-40) supplemented with 25 μl/ml complete protease
inhibitor mix and 2.5 μl/ml sodium orthovanadate to
frozen cell pellets. The viscous solution was passed sev-
eral times through a syringe fitted with a 27G needle.
After centrifugation at 13.000 rpm for 15 minutes, the
supernatant containing the extracted protein was
collected.
Immunoblotting
Western blot was performed as described elsewhere
[41]. Primary antibodies against Aurora-A, pERK, pS6,
and pRB were purchased from Cell Signaling (Danvers,
MA). p53 and Cyclin D1 antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA) and a
ß-Actin antibody was obtained from Novus Biologicals
(Cambridge, UK).
Northern Blot and expression arrays
Total RNA was prepared as described [44]. RNA ana-
lyses by Northern blotting were performed as described
before [45]. BD Atlas cDNA Expression Array analyses
were performed with total RNA according to the manu-
facturer’s protocol (BD Biosciences Clontech, Franklin
Lakes, NJ).
Abbreviations
AURKA-Aurora-A: AurA
K162R - Aurora-A mutated at Arginine 162; CDK: cyclin-
dependent kinase; ERK: extracellular signal-regulated kinase; MAPK: mitogen-
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iodide; p53
V143A: p53 mutated at Valin 143; RB: retinoblastoma gene product;
wt: wildtype.
Acknowledgements
We are thankful to Gerald Siegwart for skillful technical assistance as well as
Barbara Haigl and Rosana Kral for discussing and proofreading the
manuscript. Furthermore, we want to thank Irene Herbaceck for analyzing
the PI-stainings.
This work was supported by the “Fonds der Stadt Wien für Innovative
Interdisziplinäre Krebsforschung”, project number K-22/05 and
Herzfelder’sche Familienstiftung.
Author details
1Institute of Cancer Research, Comprehensive Cancer Center, Medical
University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.
2Helmholtz
Zentrum München (German Research Center for Environmental Health),
Marchioninistrasse 25, D-81377 Munich, Germany.
Authors’ contributions
FJ performed most of the experiments, participated in designing the study,
analyzing the data and drafting the manuscript, CP and CM were involved
in cloning and constructing adenoviruses, WB participated in design of the
study, HS conceived of the study, and participated in its design and helped
to analyse the data and draft the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 October 2010 Accepted: 16 March 2011
Published: 16 March 2011
References
1. Adams RR, Carmena M, Earnshaw WC: Chromosomal passengers and the
(aurora) ABCs of mitosis. Trends Cell Biol 2001, 11:49-54.
2. Andrews PD, Knatko E, Moore WJ, Swedlow JR: Mitotic mechanics: the
auroras come into view. Curr Opin Cell Biol 2003, 15:672-83.
3. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV: Aurora A, meiosis and
mitosis. Biol Cell 2004, 96:215-29.
4. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al: Tumour
amplified kinase STK15/BTAK induces centrosome amplification,
aneuploidy and transformation. Nat Genet 1998, 20:189-93.
5. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al:
Aurora-A and an interacting activator, the LIM protein Ajuba, are
required for mitotic commitment in human cells. Cell 2003, 114:585-98.
6. Dutertre S, Cazales M, Quaranta M, Froment C, Trabut V, Dozier C, et al:
Phosphorylation of CDC25B by Aurora-A at the centrosome contributes
to the G2-M transition. J Cell Sci 2004, 117:2523-31.
7. Dutertre S, Prigent C: Aurora-A overexpression leads to override of the
microtubule-kinetochore attachment checkpoint. Mol Interv 2003,
3:127-30.
8. Meraldi P, Honda R, Nigg EA: Aurora-A overexpression reveals
tetraploidization as a major route to centrosome amplification in p53-/-
cells. Embo J 2002, 21:483-92.
Jantscher et al. Molecular Cancer 2011, 10:28
http://www.molecular-cancer.com/content/10/1/28
Page 11 of 129. Miyoshi Y, Iwao K, Egawa C, Noguchi S: Association of centrosomal kinase
STK15/BTAK mRNA expression with chromosomal instability in human
breast cancers. Int J Cancer 2001, 92:370-3.
10. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al: A
homologue of Drosophila aurora kinase is oncogenic and amplified in
human colorectal cancers. Embo J 1998, 17:3052-65.
11. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, et al:
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human
pancreatic cancer. Clin Cancer Res 2003, 9:991-7.
12. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, et al:
Amplification/overexpression of a mitotic kinase gene in human bladder
cancer. J Natl Cancer Inst 2002, 94:1320-9.
13. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, et al:
Tumour-amplified kinase BTAK is amplified and overexpressed in gastric
cancers with possible involvement in aneuploid formation. Br J Cancer
2001, 84:824-31.
14. Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev
Cancer 2004, 4:927-36.
15. Zhang D, Hirota T, Marumoto T, Shimizu M, Kunitoku N, Sasayama T, et al:
Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic
abnormalities and hyperplasia in mammary glands of mouse models.
Oncogene 2004, 23:8720-30.
16. Fukuda T, Mishina Y, Walker MP, DiAugustine RP: Conditional transgenic
system for mouse aurora a kinase: degradation by the ubiquitin
proteasome pathway controls the level of the transgenic protein. Mol
Cell Biol 2005, 25:5270-81.
17. Li CC, Chu HY, Yang CW, Chou CK, Tsai TF: Aurora-A overexpression in
mouse liver causes p53-dependent premitotic arrest during liver
regeneration. Mol Cancer Res 2009, 7:678-88.
18. Lu LY, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, et al: Aurora A
is essential for early embryonic development and tumor suppression. J
Biol Chem 2008, 283:31785-90.
19. Pirker C, Lotsch D, Spiegl-Kreinecker S, Jantscher F, Sutterluty H,
Micksche M, et al: Response of experimental malignant melanoma
models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol
19:1040-7.
20. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, et al: Aurora-A
abrogation of p53 DNA binding and transactivation activity by
phosphorylation of serine 215. J Biol Chem 2004, 279:52175-82.
21. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al:
Phosphorylation by aurora kinase A induces Mdm2-mediated
destabilization and inhibition of p53. Nat Genet 2004, 36:55-62.
22. Willis A, Jung EJ, Wakefield T, Chen X: Mutant p53 exerts a dominant
negative effect by preventing wild-type p53 from binding to the
promoter of its target genes. Oncogene 2004, 23:2330-8.
23. Rong R, Jiang LY, Sheikh MS, Huang Y: Mitotic kinase Aurora-A
phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule
interaction and M-phase cell cycle regulation. Oncogene 2007, 26:7700-8.
24. Gigoux V, L’Hoste S, Raynaud F, Camonis J, Garbay C: Identification of
Aurora kinases as RasGAP Src homology 3 domain-binding proteins. J
Biol Chem 2002, 277:23742-6.
25. Sherr CJ, Roberts JM: Living with or without cyclins and cyclin-dependent
kinases. Genes Dev 2004, 18:2699-711.
26. Connell-Crowley L, Harper JW, Goodrich DW: Cyclin D1/Cdk4 regulates
retinoblastoma protein-mediated cell cycle arrest by site-specific
phosphorylation. Mol Biol Cell 1997, 8:287-301.
27. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA: HEF1-
dependent Aurora A activation induces disassembly of the primary
cilium. Cell 2007, 129:1351-63.
28. Mori D, Yamada M, Mimori-Kiyosue Y, Shirai Y, Suzuki A, Ohno S, et al: An
essential role of the aPKC-Aurora A-NDEL1 pathway in neurite
elongation by modulation of microtubule dynamics. Nat Cell Biol 2009,
11:1057-68.
29. Lee CY, Andersen RO, Cabernard C, Manning L, Tran KD, Lanskey MJ, et al:
Drosophila Aurora-A kinase inhibits neuroblast self-renewal by
regulating aPKC/Numb cortical polarity and spindle orientation. Genes
Dev 2006, 20:3464-74.
30. Wang H, Somers GW, Bashirullah A, Heberlein U, Yu F, Chia W: Aurora-A
acts as a tumor suppressor and regulates self-renewal of Drosophila
neuroblasts. Genes Dev 2006, 20:3453-63.
31. Lens SM, Voest EE, Medema RH: Shared and separate functions of polo-
like kinases and aurora kinases in cancer. Nat Rev Cancer 10:825-41.
32. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, et al: Aurora-A
kinase maintains the fidelity of early and late mitotic events in HeLa
cells. J Biol Chem 2003, 278:51786-95.
33. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al:
MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole
and chromosome congression defects leading to aneuploidy. Mol Cell
Biol 2007, 27:4513-25.
34. Reed CA, Mayhew CN, McClendon AK, Knudsen ES: Unique impact of RB
loss on hepatic proliferation: tumorigenic stresses uncover distinct
pathways of cell cycle control. J Biol Chem 2010, 285:1089-96.
35. Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant
protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-26.
36. Finch PW, Rubin JS: Keratinocyte growth factor/fibroblast growth factor
7, a homeostatic factor with therapeutic potential for epithelial
protection and repair. Adv Cancer Res 2004, 91:69-136.
37. Lademann UA, Romer MU: Regulation of programmed cell death by
plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost 2008,
100:1041-6.
38. Baxter RC: Signalling pathways involved in antiproliferative effects of
IGFBP-3: a review. Mol Pathol 2001, 54:145-8.
39. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras
provokes premature cell senescence associated with accumulation of
p53 and p16INK4a. Cell 1997, 88:593-602.
40. Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H,
Micksche M, et al: Response of experimental malginant melanoma
models to the pan-Aurora kinase inhibitor VE-465. Experimental
Dermatology 2010, 19(12):1040-7.
41. Mayer CE, Haigl B, Jantscher F, Siegwart G, Grusch M, Berger W, et al:
Bimodal expression of Sprouty2 during the cell cycle is mediated by
phase-specific Ras/MAPK and c-Cbl activities. Cell Mol Life Sci 2010,
67:3299-311.
42. Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, et al:
Down-Regulation of Sprouty2 in Non-Small Cell Lung Cancer
Contributes to Tumor Malignancy via Extracellular Signal-Regulated
Kinase Pathway-Dependent and -Independent Mechanisms. Mol Cancer
Res 2007, 5:509-20.
43. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, et al:
p45SKP2 promotes p27Kip1 degradation and induces S phase in
quiescent cells. Nat Cell Biol 1999, 1:207-14.
44. Haigl B, Mayer CE, Siegwart G, Sutterluty H: Sprouty4 levels are increased
under hypoxic conditions by enhanced mRNA stability and transcription.
Biol Chem 2010, 391:813-21.
45. Sutterluety H, Bartl S, Doetzlhofer A, Khier H, Wintersberger E, Seiser C:
Growth-regulated antisense transcription of the mouse thymidine kinase
gene. Nucleic Acids Res 1998, 26:4989-95.
doi:10.1186/1476-4598-10-28
Cite this article as: Jantscher et al.: Overexpression of Aurora-A in
primary cells interferes with S-phase entry by diminishing Cyclin D1
dependent activities. Molecular Cancer 2011 10:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jantscher et al. Molecular Cancer 2011, 10:28
http://www.molecular-cancer.com/content/10/1/28
Page 12 of 12